OneSource Notches a Second Generic Semaglutide Approval in Canada, Through Partner

Why It Matters

The entry of low‑cost generic semaglutide in Canada will pressure pricing and expand access to a high‑demand diabetes drug, while cementing OneSource’s reputation as a leading CDMO for complex biologics.

Key Takeaways

• Apotex, via Orbicular, secures Canada’s second generic Ozempic approval.
• OneSource provides end‑to‑end manufacturing for the Canadian filing.
• Generic semaglutide expected to cut Canadian patient costs by up to 90%.
• OneSource’s Bengaluru plant supports both Canadian and U.S. supply chains.
• Partnerships with Dr Reddy’s and Orbicular position OneSource as CDMO leader.

Pulse Analysis

The approval of a second generic semaglutide injection in Canada marks a watershed moment for the country’s diabetes therapeutics market. Health Canada, the first G7 regulator to green‑light a biosimilar version of Ozempic, highlighted potential savings of 45 % to 90 % compared with the brand product. With seven applications under review, the competitive landscape is rapidly evolving, and the entry of Apotex’s product, developed through Orbicular, underscores the growing appetite for affordable GLP‑1 alternatives among patients and payers.

OneSource Specialty Pharma’s role in the approval illustrates the power of its integrated CDMO model. Orbicular led peptide development while OneSource supplied end‑to‑end manufacturing, leveraging its FDA‑approved flagship facility in Bengaluru for commercial supply to both Canada and the United States. This seamless handoff reduces time‑to‑market and mitigates regulatory risk, positioning OneSource as a preferred partner for multinational pharma companies seeking to launch complex drug‑device combinations in highly regulated jurisdictions.

The commercial impact extends beyond price reductions. By securing generic status in a market that values cost‑effectiveness, OneSource can capture a share of the lucrative GLP‑1 segment, which is projected to exceed $30 billion globally by 2030. The partnership network—including Dr Reddy’s earlier Canadian approval—demonstrates a scalable blueprint for future biologic generics. As more patents expire, CDMOs that combine technical expertise with robust manufacturing capacity are likely to dominate the next wave of biosimilar growth.